Option chain shows key data for PaySign's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for PaySign.

PaySign (NASDAQ:PAYS) Stock, Option Chain

PaySign

PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized, payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.

Earnings

Earnings Beats

Fintech news covering the emerging Financial Technology services sector

Fintech

Large Cap

News

Penny Stocks

Offerings

Small Cap

Markets

Analyst Ratings

Trading Ideas

AFRM

PAYS

Affirm Holdings, Inc. (NASDAQ: AFRM) recently unveiled results from its latest survey, highlighting consumer shopping behaviors before the holiday season of 2024.

Affirm&#39;s Survey Reveals 0% APR Option Impact, CEO Outlines Growth Plan

Mid Cap

RELY

Visa Inc. (NYSE: V) has recently launched a new service called the Money Movement Advisory Practice in the United States and Canada.

Visa to Enhance Digital Payments With New Advisory Service

Eurozone

Commodities

Global

Intraday Update

CTAS

DRCT

GMDA

LIXT

MRDB

U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones index gaining over 300 points on Wednesday.

The Dow traded up 0.78% to 39,589.55 while the NASDAQ fell 0.02% to 16,312.74. The S&amp;P 500 also rose, gaining, 0.36% to 5,222.18.

Gold Moves Higher; Velo3D Shares Plummet

PaySign Inc

Paysafe Ltd

Paysafe Limited Warrants, exercisable for one Common Share of Paysafe Limited at a price of $11.50 per share

Biotech

Health Care

General

KALV

Japan's Ministry Of Health, Labour And Welfare Has Granted KalVista Pharmaceuticals' Sebetralstat Orphan Drug Designation, The Company Has Also Submitted A New Drug Application For Sebetralstat To The Agency

IPSC

Century Therapeutics Begins Investigator-Initiated Phase 1/2 Trial of Its iPSC-Derived iNK Cell Therapy CNTY-101 In B-cell Mediated Autoimmune Diseases

TEM: 28% &#x7C; <a href="https://www.benzinga.com//node/43091693">Nancy Pelosi Reported Purchase of 50 Jan 2026 $20 Call Options In Tempus AI On January 14</a>
&nbsp;
RKLB: 8% &#x7C; <a href="https://www.tipranks.com/news/the-fly/rocket-lab-price-target-raised-to-35-from-22-at-citi?utm_source=benzinga.com&amp;utm_medium=referral">Rocket Lab price target raised to $35 from $22 at Citi</a>
&nbsp;
MMM: 5% &#x7C; <a href="https://www.benzinga.com//node/43093086">3M shares are trading higher following better-than-expected Q4 EPS and revenues.</a>

Movers

RKLB

Market-Moving News for January 21st

Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) is reshaping its portfolio in 2025, looking to prioritize high-value, large-scale projects. Although this strategy reminds of its main competitor, Newmont, which prioritizes Tier 1 assets, Barrick still aims to profit from <a target="_blank" href="https://www.benzinga.com/topic/copper" rel="noreferrer noopener">copper tailwinds</a>, finding growth outside its core commodity.
As part of this strategy, the company is considering divesting its 50% stake in the Zaldivar copper mine in Chile, co-owned with Antofagasta. Zaldivar produced 80,000 tons of copper in 2024, but its relatively small scale and significant future investment requirements have prompted Barrick to explore potential buyers.
At the moment, Barrick's efforts focus on the Reko Diq copper and gold project in Pakistan, one of the largest undeveloped copper-gold resources globally. CEO Mark Bristow highlighted the opportunity in a <a target="_blank" href="https://www.youtube.com/watch?v=BjPKJix0KPQ" rel="noreferrer noopener">recent interview</a> for the regional media outlet Dawn.
"It couldn't be better positioned as timing goes, as quality goes. All our test work shows it is probably going to be right up there in quality of concentrate among the best copper mines in the world, "he said.
Reko Diq could generate around $74 billion in free cash flow over 37 years, with reserves extending beyond 50 years through planned expansions. The first phase of the project, involving an investment of $5.5 billion, is projected to produce 200,000 tons of copper concentrate and 250,000 ounces of gold annually starting in 2029.
A second phase, requiring an additional $3.5 billion, aims to double output to 400,000 tons of copper and 500,000 ounces of gold annually.
The project has attracted significant <a target="_blank" href="https://www.benzinga.com/m-a/24/04/38336936/saudi-arabia-near-deal-for-stake-in-gold-copper-mine-project-in-pakistans-troubled-province" rel="noreferrer noopener">interest from global investors</a>, notably Saudi Arabia's Manara Minerals, a joint venture between the state-owned mining company Ma'aden and the Public Investment Fund. Discussions between Manara and the Pakistani government are ongoing, with Saudi officials wanting to invest within the next two quarters. While Barrick is open to collaboration, the company has clarified that it will not dilute its equity in the project.
Reko Diq is strategically important due to its rich copper deposits and potential to supply critical metals for the global shift toward electrification and renewable energy.
However, operating in Balochistan presents challenges. The region is known for political instability, underdeveloped infrastructure, and <a target="_blank" href="https://www.benzinga.com/news/24/10/41311099/terrorism-in-pakistan-threatens-foreign-mine-development-saudi-arabia-still-invests-billions" rel="noreferrer noopener">security risks</a>, which could complicate project execution and deter foreign investment.
Despite the hurdles, Bristow remains optimistic about the project.
"If we prove that we can do it, which I have no doubt that we'll definitely do, that'll attract some of the big copper players to Pakistan, and that's why I refer to it as the new frontier of mining, "he noted.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/financing/25/01/43082286/australia-bets-big-on-aluminum-1-25-billion-boost-to-smelters-fuels-green-energy-push" target="_blank" rel="noreferrer noopener">Australia Bets Big On Aluminum, $1.25 Billion Boost To Smelters Fuels Green Energy Push</a></li>
</ul>
Photo via Shutterstock

Guidance

GOLD

Barrick Looks Into Portfolio Optimization, Sees Pakistan As 'The New Frontier'

Morgan Stanley analyst Erik Woodring maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Overweight and lowers the price target from $133 to $129.

Price Target

Morgan Stanley Maintains Overweight on Seagate Tech Hldgs, Lowers Price Target to $129

U.S. stocks could open on a positive note on Tuesday after <a href="https://www.benzinga.com/government/regulations/25/01/43085323/trump-sworn-in-as-47th-president-declares-golden-age-of-america-begins-right-now">Donald Trump's inauguration</a> as the 47th President of the U.S. on Monday.
Futures point to a positive start to the Trump presidency amid a cloud of tariff threats against other countries and a slew of executive orders. These include Trump revoking President Biden's EV mandate, refocusing on energy, and ordering the government's employee base to be reduced.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.46%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.40%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.37%</td>
</tr>
<tr>
<td>R2K</td>
<td>0.68%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Tuesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) gained 0.45% to $600.24 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.50% to $524.35, according to<a href="https://benzinga.grsm.io/lxquj26b2sag"> Benzinga Pro data</a>.
Cues From Last Session:
U.S. stocks ended Friday on a positive note, with the Nasdaq and S&amp;P 500 ending the day with major gains, while the Dow Jones closed 0.78% in the green.
Crude oil prices edged lower as traders await clarity about the new Trump administration's agenda.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) were among the top gainers on Friday, surging 3% during the session.
On the economic data front, U.S. industrial production rose by 0.9% in December, topping market estimates of a 0.3% increase. Housing starts rose by 15.8% from the previous month to an annualized rate of 1.499 million units in December.
Most sectors on the S&amp;P 500 closed on a positive note, with consumer discretionary, information technology, and communication services stocks recording gains on Friday.
However, healthcare and real estate stocks bucked the overall market trend, closing the session lower.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>1.51%</td>
<td>19,630.20</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>1.00%</td>
<td>5,996.66</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.78%</td>
<td>43,487.83</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.40%</td>
<td>2,275.88</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Analysts at JPMorgan sounded optimistic about the earnings growth prospects of U.S. companies over their European rivals, but the reason for this is slightly different.
According to JPMorgan strategist Mislav Matejka, the optimism stems from the fact that projections for the U.S. benchmark were "meaningfully" reduced despite a strong economy, according <a href="https://www.bloomberg.com/news/articles/2025-01-20/jpmorgan-s-matejka-sees-us-profits-outshining-europe-this-season">to</a> a report by Bloomberg.
On the other hand, expectations were "more punchy" for European stocks, which could be challenging for companies to meet.
See Also:<a href="https://www.benzinga.com/money/how-to-trade-futures"> How To Trade Futures</a>
Upcoming Economic Data
While there are no economic events scheduled for Tuesday, here's what investors will keep an eye on for the rest of the week:
<ul>
<li>On Wednesday, leading economic indicator data will be released at 10:00 a.m., ET.</li>
<li>On Thursday, initial jobless claims data will be released at 8:30 a.m. ET.</li>
<li>On Friday, S&amp;P flash services PMI and manufacturing PMI will be released at 9:45 a.m. ET.</li>
<li>Existing home sales and consumer sentiment data will be released at 10 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Auto stocks like Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>), General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), and Lucid Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>), among others, will be in focus on Tuesday.</li>
<li>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) gained 3.10% in pre-market trading President Trump revoked the Biden administration's AI order.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) stock fell nearly 2% after a rare downgrade from Jefferies, <a href="https://www.benzinga.com/markets/equities/25/01/43087992/apple-gets-rare-downgrade-from-jefferies-analyst-warns-on-slowing-revenue-growth-missed-forecasts-and-falling-iphone-demand">citing slowing revenue growth and iPhone demand</a>.</li>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) continued to soar amid reports of the chipmaker being the target of an acquisition bid.</li>
<li>Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) edged up by 0.8% ahead of its earnings scheduled for later today.</li>
<li>Trump Media &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) <a href="https://www.benzinga.com/general/social-media/25/01/43091739/djt-stock-drops-3-in-tuesday-premarket-a-day-after-inauguration-key-details-about-trumps-media-company">shares fell more than 7% in pre-market</a> after President Trump's inauguration.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures fell in the early New York session, declining by 2.5% to hover around $75.30 per barrel.
The 10-year Treasury note yield edged lower to 4.587%.
Most of the major Asian markets were mixed on Tuesday, while European markets were in the red in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/01/43091739/djt-stock-drops-3-in-tuesday-premarket-a-day-after-inauguration-key-details-about-trumps-media-company">DJT Stock Drops 3% In Tuesday Premarket, A Day After Inauguration — Key Details About Trump&#8217;s Media Company</a></li>
</ul>
Photo Via Shutterstock

Equities

Futures

Economics

Federal Reserve

Pre-Market Outlook

AAPL

INTC

LCID

NFLX

NVDA

RIVN

TSLA

US Stocks Set To Open On A Positive Note As Trump's Second White House Term Kicks Off: Tesla, Apple, Netflix Among Stocks In Focus

Citigroup analyst Jason Gursky initiates coverage on Curtiss-Wright (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>) with a Buy rating and announces Price Target of $410.

Initiation

Citigroup Initiates Coverage On Curtiss-Wright with Buy Rating, Announces Price Target of $410

Morgan Stanley analyst Hamza Fodderwala maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Overweight and raises the price target from $223 to $230.

PANW

Morgan Stanley Maintains Overweight on Palo Alto Networks, Raises Price Target to $230

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Morgan Stanley analyst John Glass downgraded the rating for Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) from Overweight to Equal-Weight and lowered the price target from $158 to $140. Yum Brands shares closed at $125.32 on Friday. <a href="https://www.benzinga.com/quote/YUM/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">how other analysts view this stock</a>.</li>
<li>Jefferies analyst Kyle Mcnealy downgraded Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) from Hold to Underperform and lowered the price target from $211.84 to $200.75. Apple shares closed at $229.98 on Friday. <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Alex Straton downgraded Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) from Overweight to Equal-Weight and cut the price target from $164 to $140. Ross Stores shares closed at $149.15 on Friday. <a href="https://www.benzinga.com/quote/ROST/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Benjamin Theurer downgraded the rating for Bunge Global SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) from Overweight to Equal-Weight and lowered the price target from $115 to $95. Bunge Global shares closed at $79.54 on Friday. <a href="https://www.benzinga.com/quote/BG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Benjamin Theurer downgraded CF Industries Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) from Overweight to Equal-Weight but raised the price target from $96 to $100. CF Industries shares closed at $97.01 on Friday. <a href="https://www.benzinga.com/quote/CF/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="564" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21070908/image-133-1024x564.png" alt="" class="wp-image-742291" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21070908/image-133-1024x564.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21070908/image-133-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21070908/image-133-768x423.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/21070908/image-133.png 1131w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43091705/top-4-health-care-stocks-you-may-want-to-dump-in-q1">Top 4 Health Care Stocks You May Want To Dump In Q1</a></li>
</ul>

Downgrades

ROST

This Apple Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Citigroup analyst Jason Gursky upgrades RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) from Neutral to Buy and raises the price target from $132 to $153.

Upgrades

Citigroup Upgrades RTX to Buy, Raises Price Target to $153

– Presented data includes a 97% Calculated Objective Response Rate (ORR) of study subjects following treatment with VP-315
– Posters highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance
WEST CHESTER, Pa., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrca#NASDAQ">VRCA</a>), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the presentation of three posters that were presented at the 2025 Winter Clinical Dermatology Conference, which was held from January 17-19, in Miami, Florida. The posters featured clinical data from Part 2 of the Phase 2 study (the "Study") of the Company's novel oncolytic peptide, VP-315, for the treatment of basal cell carcinoma ("BCC").
Verrica presented a poster titled "Calculated Objective Response Rate (ORR) of 97% from Post-Hoc Analysis of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational therapy for Basal Cell Carcinoma (BCC)" while encore presentations of two additional posters (titled "Results of a Phase 2 Multicenter Study Evaluating the Safety and Tolerability of VP-315, an Investigational therapy for Basal Cell Carcinoma" and "Results of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational Therapy for Basal Cell Carcinoma") were also made at the conference. The posters included safety and histologic clearance data from 82 patients with up to two target BCC tumors (a total of 91 tumors) in Part 2 of the Study evaluating VP-315 for the treatment of BCC, including patients with tumors on the head and neck.
Part 2 of the Study was designed to explore dosing regimens to help Verrica identify the recommended regimen for a Phase 3 study program. Approximately 51% of tumors treated in the Study achieved complete histological clearance, while those patients with a residual tumor achieved, on average, approximately 71% reduction in tumor size. There were no Treatment Related Serious Adverse Events, and most Treatment Related Adverse Events were mild to moderate.
In the newly-presented poster, Verrica conducted a post-hoc analysis of the data from the Study and announced a Calculated ORR of 97%, defined as the percentage of study subjects who do not demonstrate disease progression and who experience at least a 30% level of tumor reduction along with partial or complete response following treatment The Company still expects genomic and T-cell (immune response) data in the first quarter of 2025 and plans to request an End-of-Phase 2 meeting with the FDA in the first half of 2025 to determine the next steps for the development of VP-315 for the treatment of BCC.

VRCA

Verrica Pharmaceuticals To Present 3 Posters Featuring Preliminary Topline Results Of VP-315 For The Treatment Of Basal Cell Carcinoma, Including A 97% Calculated Objective Response Rate Of Study Subjects Following Treatment With VP-315 At The 2025 Winter Clinical Dermatology Conference

<h3>Gainers</h3>
<ul>
<li>Envela (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELA#AMEX">ELA</a>) shares rose 17.7% to $8.39 during Tuesday's pre-market session. The company's market cap stands at $218.1 million. </li>
<li>Chijet Motor Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) stock moved upwards by 14.52% to $2.01. The market value of their outstanding shares is at $14.1 million. </li>
<li>Premium Catering (Hldgs) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PC#NASDAQ">PC</a>) stock moved upwards by 11.21% to $0.8. The market value of their outstanding shares is at $12.8 million. </li>
<li>Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) stock moved upwards by 9.89% to $0.53. The market value of their outstanding shares is at $7.9 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) stock rose 8.26% to $2.49. The market value of their outstanding shares is at $9.7 million. </li>
<li>Zapp Electric Vehicles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) shares moved upwards by 8.03% to $1.21. The company's market cap stands at $5.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Canoo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) stock declined by 73.4% to $0.36 during Tuesday's pre-market session. The company's market cap stands at $5.1 million. </li>
<li>New Oriental Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDU#NYSE">EDU</a>) stock declined by 12.56% to $53.2. The market value of their outstanding shares is at $8.6 billion. The company's, Q2 earnings came out today. </li>
<li>AYRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>) stock fell 8.91% to $0.64. The company's market cap stands at $4.3 million. </li>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) stock declined by 8.36% to $0.67. The market value of their outstanding shares is at $14.1 million. </li>
<li>Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) shares fell 6.59% to $126.6. The market value of their outstanding shares is at $34.7 billion. </li>
<li>Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) stock decreased by 6.49% to $2.74. The company's market cap stands at $9.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALUR

AYRO

CJET

New Oriental Education & Technology Group

GDHG

GOEV

VEEE

ZAPP

12 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock rose 47.8% to $1.11 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.1 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares increased by 36.89% to $2.56. The market value of their outstanding shares is at $3.4 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) shares rose 19.82% to $1.39. The market value of their outstanding shares is at $3.8 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock increased by 19.75% to $6.75. The company's market cap stands at $8.6 million. </li>
<li>Tempus AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) shares rose 19.14% to $41.88. The company's market cap stands at $6.5 billion. </li>
<li>Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) stock rose 17.39% to $5.94. The company's market cap stands at $336.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Baird Medical Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) shares declined by 14.1% to $7.6 during Tuesday's pre-market session. The market value of their outstanding shares is at $276.3 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares fell 12.47% to $0.13. The market value of their outstanding shares is at $10.7 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock decreased by 10.94% to $0.57. The company's market cap stands at $10.4 million. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock fell 10.64% to $2.52. The market value of their outstanding shares is at $124.9 million. </li>
<li>Rapid Micro Biosystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPID#NASDAQ">RPID</a>) shares fell 9.76% to $1.11. The company's market cap stands at $47.7 million. </li>
<li>Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) stock decreased by 9.1% to $310.0. The company's market cap stands at $8.8 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

AKYA

BDMD

BMRA

DSGN

DWTX

HSDT

RDHL

RPID

TNFA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Innovate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VATE#NYSE">VATE</a>) shares increased by 22.5% to $6.26 during Tuesday's pre-market session. The market value of their outstanding shares is at $83.0 million. </li>
<li>Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) stock moved upwards by 10.64% to $16.32. The market value of their outstanding shares is at $1.0 billion. </li>
<li>Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) shares moved upwards by 9.69% to $4.3. The company's market cap stands at $212.2 million. </li>
<li>ACCO Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACCO#NYSE">ACCO</a>) shares rose 9.42% to $5.69. The market value of their outstanding shares is at $544.1 million. </li>
<li>Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) shares increased by 7.44% to $3.61. The company's market cap stands at $399.1 million. </li>
<li>PS International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares increased by 6.97% to $0.44. The company's market cap stands at $10.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Graphex Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GRFX#AMEX">GRFX</a>) stock decreased by 15.9% to $0.26 during Tuesday's pre-market session. The company's market cap stands at $15.2 million. </li>
<li>Nocera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCRA#NASDAQ">NCRA</a>) stock declined by 8.26% to $1.0. The market value of their outstanding shares is at $14.0 million. </li>
<li>SES AI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) shares decreased by 6.46% to $0.87. The company's market cap stands at $311.1 million. </li>
<li>Staffing 360 Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAF#NASDAQ">STAF</a>) shares fell 5.94% to $3.17. The company's market cap stands at $4.8 million. </li>
<li>Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) shares decreased by 5.71% to $2.81. The market value of their outstanding shares is at $152.2 million. </li>
<li>Multi Ways Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MWG#AMEX">MWG</a>) stock decreased by 5.58% to $0.27. The market value of their outstanding shares is at $8.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACCO

AMPX

BAER

CRGO

GRFX

NCRA

PSIG

STAF

VATE

12 Industrials Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>X3 Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) stock rose 19.9% to $1.19 during Tuesday's pre-market session. The market value of their outstanding shares is at $16.3 million. </li>
<li>Logility Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGTY#NASDAQ">LGTY</a>) shares increased by 12.52% to $12.4. The company's market cap stands at $417.6 million. </li>
<li>Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) stock moved upwards by 10.44% to $2.22. The company's market cap stands at $638.7 million. </li>
<li>SatixFy Communications (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SATX#AMEX">SATX</a>) stock increased by 9.85% to $1.56. The market value of their outstanding shares is at $130.3 million. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) stock moved upwards by 9.59% to $8.45. The market value of their outstanding shares is at $130.3 million. </li>
<li>WISeKey Intl Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKEY#NASDAQ">WKEY</a>) stock increased by 8.69% to $8.0. The market value of their outstanding shares is at $89.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) stock decreased by 25.0% to $0.84 during Tuesday's pre-market session. The company's market cap stands at $19.4 million. </li>
<li>BTC Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCT#NASDAQ">BTCT</a>) stock decreased by 10.9% to $7.36. The market value of their outstanding shares is at $38.6 million. </li>
<li>PicoCELA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCLA#NASDAQ">PCLA</a>) stock declined by 10.08% to $2.32. The market value of their outstanding shares is at $57.2 million. </li>
<li>Sobr Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) stock declined by 8.5% to $0.86. </li>
<li>CISO Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISO#NASDAQ">CISO</a>) stock declined by 7.77% to $0.95. The company's market cap stands at $11.2 million. </li>
<li>Intellinetics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INLX#AMEX">INLX</a>) stock declined by 6.84% to $12.0. The company's market cap stands at $50.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTCT

CISO

INLX

LGTY

ORKT

PCLA

SatixFy Communications Ltd. Ordinary Share

SATX

SOBR

WKEY

XTKG

12 Information Technology Stocks Moving In Tuesday's Pre-Market Session

Old National Bancorp Reported Q4 Return On Average Tangible Common Equity Of 16.4%; Adjusted Of 17.0%, With Preliminary Regulatory Tier 1 Common Equity To Risk-weighted Assets Of 11.38%, Up 38 BPS

Needham analyst Ryan Koontz reiterates Lantronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRX#NASDAQ">LTRX</a>) with a Buy and maintains $5.5 price target.

Reiteration

LTRX

Needham Reiterates Buy on Lantronix, Maintains $5.5 Price Target

Contracts

GILT

Gilat Bags $5M To Improve Defense Forces Connectivity

Citigroup analyst Jason Gursky initiates coverage on V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) with a Buy rating and announces Price Target of $64.

Citigroup Initiates Coverage On V2X with Buy Rating, Announces Price Target of $64

Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.46 by 6.52 percent. This is a 6.52 percent increase over earnings of $0.46 per share from the same period last year. The company reported quarterly sales of $489.95 million which beat the analyst consensus estimate of $485.57 million by 0.90 percent. This is a 5.48 percent increase over sales of $464.50 million the same period last year.

Old National Q4 2024 Adj EPS $0.49 Beats $0.46 Estimate, Sales $489.95M Beat $485.57M Estimate

Here are the major earnings after the close today

Paysign Non-GAAP EPS of $0.05 beats by $0.04, revenue of $15.26M beats by $0.44M

The company states: "We executed on another positive quarter with year-over-year quarterly revenues increasing 23.0% to $15.26 million and adjusted...

Paysign affirms FY24 revenue view of $56.5M-$58.5M, consensus $57.5M

Paysign, Inc. (PAYS) Q3 2024 Earnings Call Transcript

PaySign Inc Class B ( ($PAYS) ) has released its Q3 earnings. Here is a breakdown of the information PaySign Inc Class B presented to its investors...

Paysign, Inc. Reports Strong Q3 2024 Growth

In a report released today, Gary Prestopino from Barrington maintained a Buy rating on PaySign (PAYS – Research Report), with a price target of $7....

Buy Rating for PaySign Driven by Strong Financial Performance and Growth Potential

Meeting to be held in New York on November 13 at 12 pm hosted by DA Davidson. Published first on TheFly – the ultimate source for real-time, market...

Paysign management to meet with DA Davidson

Paysign Is A Leader In Fintech Healthcare Payments With Durable Profitable Growth

Conference call with management will be held on November 25 at 3 pm hosted by DA Davidson. Published first on TheFly – the ultimate source for real...

Paysign participates in a conference call with DA Davidson

Lake Street initiated coverage of Paysign (PAYS) with a Buy rating and $6 price target Paysign is a "market leader" in prepaid plasma donor incenti...

Paysign initiated with a Buy at Lake Street

AVNW

BBAI

BCSF

CGBD

CPNG

EOSE

EXAS

GMED

GPOR

IGIC

IRBT

JKHY

LAAC

LUMN

MASI

MCHP

MEGEF

MGNX

MRCY

NCMI

PAAS

QLYS

RARE

RVLV

RYAM

RYTM

SMCI

SNDX

STKL

TFPM

TRVG

TSLX

WTTR

Press Releases

Paysign, Inc. to Participate in the June 2024 Sidoti Small-Cap Virtual Investor Conference

Paysign, Inc. to Participate in the 2024 iAccess Alpha Buyside Best Ideas Summer Conference

Paysign, Inc. to Participate in the 2024 Maxim Fintech Virtual Symposium, June 25

Events

iAccess Alpha's Buyside Best Ideas Virtual Summer Conference June 25-26, 2024

Paysign to Host Second Quarter 2024 Earnings Call

Comments

PaySign

PaySign (PAYS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga